Ad is loading...
REMIX
Price
$14.94
Change
-$0.14 (-0.93%)
Updated
Nov 15 closing price
SPEDX
Price
$20.41
Change
-$0.21 (-1.02%)
Updated
Nov 15 closing price
Ad is loading...

REMIX vs SPEDX

Header iconREMIX vs SPEDX Comparison
Open Charts REMIX vs SPEDXBanner chart's image
Standpoint Multi-Asset Investor
Price$14.94
Change-$0.14 (-0.93%)
VolumeN/A
CapitalizationN/A
Alger Dynamic Opportunities A
Price$20.41
Change-$0.21 (-1.02%)
VolumeN/A
CapitalizationN/A
REMIX vs SPEDX Comparison Chart
Loading...
View a ticker or compare two or three
VS
REMIX vs. SPEDX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REMIX is a StrongBuy and SPEDX is a StrongBuy.

FUNDAMENTALS
Fundamentals
REMIX has more cash in the bank: 1.02B vs. SPEDX (206M). REMIX pays higher dividends than SPEDX: REMIX (0.52) vs SPEDX (0.00). REMIX was incepted earlier than SPEDX: REMIX (5 years) vs SPEDX (15 years). SPEDX is a more actively managed with annual turnover of: 350.56 vs. REMIX (8.00). SPEDX has a lower initial minimum investment than REMIX: SPEDX (1000) vs REMIX (2500). SPEDX annual gain was more profitable for investors over the last year : 28.61 vs. REMIX (10.20).
REMIXSPEDXREMIX / SPEDX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence5 years15 years-
Gain YTD12.16220.20060%
Front LoadN/AN/A-
Min. Initial Investment25001000250%
Min. Initial Investment IRAN/AN/A-
Net Assets1.02B206M497%
Annual Yield % from dividends0.520.00-
Returns for 1 year10.2028.6136%
Returns for 3 years11.18-5.64-198%
Returns for 5 yearsN/A44.65-
Returns for 10 yearsN/A58.71-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PCG21.040.05
+0.24%
PG&E Corp
SKY97.08N/A
N/A
Champion Homes Inc
ULH48.87-0.16
-0.33%
Universal Logistics Holdings
INBK40.24-0.31
-0.76%
First Internet Bancorp
CARM0.88-0.06
-5.93%
Carisma Therapeutics